Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A

SSZSE:301246
14.66
CNY
-0.16
(-1.08%)
0.76EPS
22.86P/E
7.02BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
13.46
3.43
3.11
2.98
3.63
3.77
4.46
3.7
4.47
5.85
5.29
4.44
4.89
6.46
Basic EPS, GAAP
0.4
0.22
0.2
0.18
0.09
0.03
0.89
0.73
1.4
1.23
0.22
0.13
0.3
0.77
Free Cash Flow per Basic Share
-0.09
0.2
0.15
-0.17
-0.66
0.36
0.37
0.24
-0.18
-0.83
-1.13
-0.44
-0.86
- -
Dividend per Share
0.53
0.07
0.07
0.06
0.06
0.09
0.08
0.02
0.01
0.04
0.14
0.08
0.07
0.09
Book Value per Share
0.45
0.73
1.42
1.61
1.7
1.74
2.63
3.36
4.76
5.99
10.9
10.9
11.15
11.6
Tangible Book Value per Share
0.35
0.56
0.9
1.12
1.23
1.49
2.4
3.14
4.21
5.5
10.44
10.45
10.7
11.17
Basic Weighted Avg Shares
70
300
323
361
353
352
353
352
353
353
388
399
397
397
Sales/Revenue/Turnover
947
1,031
1,003
1,075
1,278
1,329
1,574
1,303
1,578
2,064
2,055
1,771
1,939
2,564
Operating Margin (%)
6.92
9.99
10.81
11.76
5.94
10.66
25.55
27.78
23.74
15.98
5.37
4.86
9.2
14.24
Depreciation Expense
31
33
42
66
81
75
78
74
80
90
157
179
202
- -
Net Income, GAAP
28
66
65
65
33
12
314
257
494
435
87
51
119
304
Effective Tax Rate (%)
16.09
14.78
14.63
17.19
13.99
51.16
16.67
15.85
9.39
9.03
11.56
13.79
19.27
19.27
Profit Margin (%)
2.97
6.41
6.44
6.04
2.58
0.91
19.93
19.74
31.3
21.07
4.24
2.91
6.14
11.87
Working Capital
-202
-90
-76
-86
-182
-269
298
438
412
345
2,287
1,910
2,056
1,943
LT Debt
19
50
110
128
250
138
86
8
55
350
283
238
375
474
Total Equity
168
257
509
574
607
613
927
1,184
1,678
2,114
4,360
4,361
4,459
4,639
Return on Invested Capital (%)
4.33
10.52
8.47
7.85
2.89
1.14
30.43
21.32
31.79
20.07
2.57
1.1
2.62
- -
Return on Capital (%)
12.65
18.48
12.39
9.5
5.14
4.33
44.9
27.25
32.57
20.49
2.73
1.31
2.71
- -
Return on Common Equity (%)
19.54
31.8
17.01
12.15
5.64
2
40.76
24.36
34.51
22.93
2.69
1.18
2.7
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
170
201
192
LT Borrowings
425
450
468
LT Finance Leases
6
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
400
400
400
Market Capitalization
9,244
10,760
7,016

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,341
3,328
3,185
Cash, Cash Equivalents & STI
1,592
1,561
1,679
Accounts Receivable, Net
594
515
479
Inventories
335
348
316
Total Current Liabilities
1,158
1,264
1,242
Payables & Accruals
- -
- -
- -
ST Debt
170
201
192
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.46%
35.24%
2.24%
Free Cash Flow
12.76%
54.99%
93.77%
Net Income, GAAP
244.97%
18.1%
131.33%
Sales/Revenue/Turnover
7.84%
9.43%
9.53%
Total Cash Common Dividend
67.66%
141.78%
-9.05%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
426
472
424
448
1,771
2025
433
449
- -
622
1,939
2026
704
638
599
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.01
- -
0.04
0.13
2025
0.02
-0.04
- -
0.3
0.3
2026
0.36
0.03
0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.06
- -
0.08
2025
0.01
0.04
- -
0.01
0.07
2026
0.01
0.06
0.01
- -
- -

Company Description

CEO
Dan Yin
Full Time Employees
2,258
Sector
Process industries
Industry
Chemicals: specialty
Address
Huanggang China
IPO Date
Mar 20, 2023
Business
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is a China-based chemical and pharmaceutical manufacturing company founded in 2002 and headquartered in Luotian County, Hubei Province. The company specializes in the research, development, production, and sale of fine chemical raw materials, pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished pharmaceutical preparations, and new energy electrolyte materials. Operating a vertically integrated manufacturing model, the company supplies healthcare, veterinary, and battery manufacturing sectors across mainland China and international markets throughout Asia, Europe, North America, and Africa. The company's product portfolio is organized into five primary segments: active pharmaceutical ingredients, including metronidazole, benzoyl metronidazole, dimetridazole, acyclovir, and valacyclovir hydrochloride; pharmaceutical intermediates, comprising imidazole, 2-methylimidazole, 2-methyl-5-nitroimidazole, glyoxylic acid, guanine, diacetylguanine, diacetylacyclovir, and penicillin-derivative synthesis agents; organic chemical raw materials, including glyoxal and oxalic acid; finished pharmaceutical preparations, consisting of traditional Chinese medicines and chemical pharmaceutical dosage forms such as Pudilan Xiaoyan tablets, Huoxiang Zhengqi liquid, Qingre Jiedu oral solutions, tablets, capsules, and granules across antiviral, antibacterial, anti-inflammatory, and gastrointestinal therapeutic categories; and new energy materials, featuring battery-grade lithium hexafluorophosphate (LiPF6) produced through proprietary rheological phase synthesis for lithium-ion battery electrolyte applications. The company conducts its manufacturing, research, and marketing operations through its corporate divisions and operating subsidiaries, which include Hubei Tongdetang Pharmaceutical Co., Ltd., Hubei Xinnuowei Chemical Co., Ltd., Wuhan Shuanglong Pharmaceutical Co., Ltd., Hubei Hongyuan Chemical Technology Co., Ltd., Hubei Hongyuan Fluorochemical Co., Ltd., Hubei Wanmizhai Pharmaceutical Co., Ltd., and Hubei Zhonglan Hongyuan New Energy Materials Co., Ltd. In recent corporate developments, the company completed its initial public offering and listed its Class A shares on the ChiNext board of the Shenzhen Stock Exchange under ticker symbol 301246, raising capital to fund capacity expansions across its core chemical and advanced materials facilities. In its new energy materials segment, the company completed acceptance and commercial operation of its 2,000-ton-per-year lithium hexafluorophosphate technological upgrade project and advanced development on its 6,000-ton high-purity crystalline lithium hexafluorophosphate production facility. In addition, the company continues to execute on upstream-downstream vertical integration initiatives, expanding its production capacities for key starting materials, scaling its pharmaceutical preparation manufacturing lines, and broadening international market penetration for its core nitroimidazole and antiviral intermediate product lines.